Hikma Pharmaceutical | HIK - Operating Profit

Stock Price
1,443.50
Daily Change
3.50 0.24%
Monthly
4.79%
Yearly
-30.20%
Q2 Forecast
1,414.37

Hikma Pharmaceutical reported $348M in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Almirall EUR 30.23M 12.8M Dec/2025
argenx SE USD 394M 22.86M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Autolus Therapeutics Ltd USD -59.51M 12.95M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Fresenius EUR 713M 139M Dec/2025
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GRIFOLS EUR 249M 26.38M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 474M 738M Dec/2025
Orion EUR 114.8M 213.4M Mar/2026
Recordati EUR 278.23M 112.58M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
UCB EUR 1.29B 571M Dec/2025